Skip to main content
Clinical Trials/CTRI/2022/05/042422
CTRI/2022/05/042422
Not yet recruiting
未知

A Prospective Randomized Comparative Clinical Study to Evaluate the Efficacy of Cresvin Beta Capsules in Type II Diabetes Mellitus Patients

Apex Laboratories Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: E088- Diabetes mellitus due to underlying condition with unspecified complications
Sponsor
Apex Laboratories Pvt Ltd
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Male or female patients within the age range of 18 to 60 years (both years inclusive) diagnosed with T2DM for at least 3 months.
  • \-Willingness to provide written informed consent to participate in the study.
  • \-Patients understanding the nature and purpose of the study and who are willing to comply with study procedures.
  • \-Fasting plasma glucose greater than or equal to 126 mg/dL
  • \-Random plasma glucose greater than 200 mg/dL in a person with symptoms of diabetes.
  • \-Duration of diabetes â?? Newly diagnosed diabetics or diagnosed within past 5 years
  • \-HbA1C between 7\-9\.5%

Exclusion Criteria

  • \-Type 1 diabetes mellitus
  • \-Patients with severe hyperglycemia (FBS greater than 234 mg per dl or PPBS greater than 360 mg per dl
  • \-HbA1C is more than 9\.5 per cent.
  • \-ASAT and ALT levels greater than 2\.5 times the upper normal limits
  • ï?§Severe renal, hepatic, cardiac, gastrointestinal, neurological, hematological or respiratory
  • ï?§disorders, in view of the investigator.
  • ï?§Patients with psychiatric disorder.
  • ï?§History of smoking (more than 10 cigarettes/day) or alcohol intake \> 20gm/day.

Outcomes

Primary Outcomes

Not specified

Similar Trials